查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1943515

光免疫疗法市场－全球产业规模、份额、趋势、机会及预测（依治疗领域、最终用户、地区及竞争格局划分，2021-2031年）

Photoimmunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Area, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球光免疫疗法市场预计将从 2025 年的 19.9 亿美元成长到 2031 年的 36.5 亿美元，复合年增长率为 10.64%。

这种标靶肿瘤治疗方法利用抗体-光敏剂偶联物，在近红外线光活化后，可诱导精准的细胞坏死。此领域的发展主要受固态肿瘤发生率上升以及临床上对既能保护器官功能又能限制全身毒性的治疗方法的需求所驱动。此外，大量需要有效控制局部疾病的患者族群也进一步强化了这项需求。例如，美国癌症协会报告称，2024年美国将新增约58,450例头颈癌病例，凸显了此类治疗方案的重要性。

市场概览
预测期 2027-2031
市场规模：2025年 19.9亿美元
市场规模：2031年 36.5亿美元
复合年增长率：2026-2031年 10.64%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

然而，近红外线光在生物组织中的穿透深度较浅是市场成长的主要障碍。这种物理限制使得其治疗效果仅限于浅层肿瘤或可透过内视镜触及的肿瘤，难以在不进行侵入性手术的情况下应用于深部恶性肿瘤。因此，光疗系统固有的技术复杂性仍然是一个核心挑战，并可能阻碍其在更广泛的癌症类型中的临床应用。

市场驱动因素

由于研发投入的增加和临床管线的不断拓展，光免疫疗法正迅速从实验阶段迈向商业性化治疗方法。资金对于维持后期临床试验至关重要，尤其是使用抗体-光吸收剂偶联物的专有系统需要严格的监管检验。正如2024年3月题为「乐天医疗完成1.19亿美元E轮资金筹措」的新闻稿中所强调的，乐天医疗筹集了1.19亿美元，用于加速其Alluminox平台的全球III期临床试验。这笔巨额资金筹措直接推动公司实现其战略目标，即扩大治疗方法的适应症范围，并在关键国际市场获得监管部门的核准，从而证实了精准细胞标靶治疗的商业性潜力。

同时，全球范围内不可切除的头颈癌发病率不断上升，推动了市场发展，促使人们迫切需要能够控制局部病变且避免根治性手术相关副作用的治疗方法。在传统治疗方法难以保留器官功能的高发生率地区，此因素尤其重要。根据乐天医疗株式会社2024年1月发布的题为「乐天医疗在印度成功治疗首例患者」的新闻稿，印度每年新增头颈癌病例超过20万例，这凸显了该疗法的关键目标患者群。在全球范围内，巨大的疾病负担也凸显了开发新型固体癌疗法的迫切性。世界卫生组织（WHO）2024年2月发布的报告《日益加重的全球癌症负担》估计，2022年全球将新增2000万例癌症病例，凸显了标靶治疗的巨大市场潜力，因为标靶治疗能够降低全身毒性。

市场挑战

近红外线光穿透深度较浅是限制全球光免疫疗法市场扩张的一大阻碍因素。这项物理限制使得该疗法主要局限于治疗表浅或内视镜可及的肿瘤，大大限制了效用。因此，除非与复杂的外科手术或介入治疗相结合，否则该技术在治疗常见内臟肿瘤方面面临许多挑战。这种对可近性的依赖限制了适用患者群体，并增加了临床工作流程的复杂性，阻碍了医疗机构的广泛采用，而这些医疗机构更倾向于选择能够治疗多种肿瘤类型的通用治疗方法。

这种限制的影响在治疗难以用外部光源照射的内臟恶性肿瘤时尤为显着。例如，美国癌症协会 (ACS) 估计，2024 年美国将新增 234,580 例肺癌和支气管癌病例。将足够的光能输送到这些深层组织结构是一项挑战，这降低了光免疫疗法相对于全身性治疗的竞争优势。因此，相关人员在将该治疗方法确立为主要内臟癌症适应症的一线标准治疗方案方面面临许多挑战。

市场趋势

一项重要的转变是将光免疫疗法与免疫查核点抑制剂合併应用，以增强全身性抗肿瘤免疫力。光免疫疗法透过诱导免疫抗原性细胞死亡来增强肿瘤微环境的敏感性，进而提高PD-1/PD-L1抑制剂在治疗难治性固态肿瘤的疗效。近期数据证实了这种协同效应，证实了先前接受过标准治疗的复发性头颈部鳞状细胞癌（HNSCC）患者的生存期有所改善。根据乐天医疗2025年9月发布的关于一项Ib/II期临床试验的新闻稿，ASP-1929联合治疗Pembrolizumab的中位总生存期（OS）达到25.6个月，显着超过了此前单药治疗的基准。

同时，市场的一个显着特征是临床开发倡议的全球策略扩张，旨在获得早期采用市场以外其他地区的监管核准。开发商正积极扩大临床实验，纳入多区域队列，以满足监管要求，并在欧洲和亚太地区获取可靠的数据。这一趋势在针对局部晚期癌症的后期试验中尤为明显，透过纳入更广泛的患者群体来加速商业化进程。例如，乐天医疗在2025年7月的新闻稿中宣布，已将其针对复发性头颈部鳞状细胞癌的全球3期临床试验扩大至412名患者，并在东欧新增了一个临床试验点，以加速患者招募和检验。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球光免疫疗法市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依治疗领域（头颈癌、转移性黑色素瘤、其他）
    • 按最终用户（医院/诊所、门诊护理中心、生技/製药公司、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章 北美光免疫疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲光免疫疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区光免疫疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲光免疫疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章 南美洲光免疫疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球光免疫疗法市场：SWOT分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Rakuten Medical, Inc.
  • Shimadzu Corporation
  • Modulight Corporation
  • Steba Biotech Ltd.
  • Luzitin SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 12819

The Global Photoimmunotherapy Market is projected to expand from USD 1.99 Billion in 2025 to USD 3.65 Billion by 2031, reflecting a compound annual growth rate of 10.64%. This targeted oncological approach employs an antibody-photosensitizer conjugate that, when activated by near-infrared light, triggers precise cell necrosis. Growth in this sector is primarily fueled by the rising incidence of solid tumors and the clinical necessity for therapies that maintain organ function while limiting systemic toxicity. The demand is further solidified by a significant patient base needing effective management for locoregional diseases; for instance, the American Cancer Society reported that approximately 58,450 individuals in the United States were diagnosed with head and neck cancers in 2024, emphasizing the critical need for such therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.99 Billion
Market Size 2031USD 3.65 Billion
CAGR 2026-203110.64%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Nevertheless, a major obstacle to market growth is the shallow penetration depth of near-infrared light into biological tissues. This physical limitation confines the therapy's effectiveness to tumors that are superficial or accessible via endoscopy, complicating its use for deep-seated malignancies absent invasive surgical measures. Consequently, the technical intricacies involved in light delivery systems persist as a core challenge, potentially impeding widespread clinical adoption across a broader range of cancer types.

Market Driver

Increased investment in research and development, alongside the broadening of clinical pipelines, is hastening the progression of photoimmunotherapy from experimental stages to commercially viable treatments. Financial support is essential for maintaining late-stage trials, especially for proprietary systems using antibody-photoabsorber conjugates that demand rigorous validation for regulatory authorities. As highlighted in a March 2024 press release titled "Rakuten Medical Closes $119 Million Series E Financing," Rakuten Medical raised $119 million to fast-track its global Phase 3 clinical trial of the Alluminox platform. This significant funding directly advances the strategic goal of widening the therapy's indications and securing regulatory clearance in major international markets, thereby confirming the commercial potential of precision cell-targeting therapies.

Concurrently, the market is propelled by the growing global prevalence of unresectable head and neck cancers, which necessitates interventions capable of managing locoregional disease without the adverse effects associated with radical surgery. This driver is especially critical in regions with high incidence rates where conventional treatments frequently fail to preserve organ function. According to Rakuten Medical's January 2024 press release, "Rakuten Medical Announces First Patient Treatment in India," over 200,000 new head and neck cancer cases are diagnosed annually in India, identifying a key demographic for this treatment. Globally, the urgent need for new solid tumor treatments is highlighted by the massive disease burden; the World Health Organization's February 2024 report, "Global Cancer Burden Growing," estimated 20 million new cancer cases worldwide in 2022, underscoring the vast market potential for targeted therapies offering reduced systemic toxicity.

Market Challenge

The shallow penetration capability of near-infrared light serves as a significant restraint on the expansion of the global photoimmunotherapy market. Because of this physical restriction, the therapy is largely limited to treating superficial or endoscopically reachable tumors, effectively reducing its utility for deep-seated malignancies. As a result, the technology encounters substantial obstacles in managing high-volume internal cancers unless paired with complex or invasive surgical procedures. This dependency on accessibility restricts the eligible patient pool and adds complexity to clinical workflows, which discourages widespread adoption among healthcare providers who prefer versatile treatment options for a wide array of oncology cases.

The consequences of this limitation become apparent when addressing internal malignancies that are challenging to target with external light sources. For instance, the American Cancer Society estimated that 234,580 new cases of lung and bronchus cancer were diagnosed in the United States in 2024. The challenge of delivering adequate light energy to these deep tissue structures diminishes the competitive edge of photoimmunotherapy compared to systemic treatments. Consequently, market stakeholders encounter difficulties in establishing this modality as a primary standard of care for major internal cancer indications.

Market Trends

A significant shift involves combining photoimmunotherapy with immune checkpoint inhibitors to boost systemic anti-tumor immunity. By triggering immunogenic cell death, photoimmunotherapy sensitizes the tumor microenvironment, which enhances the effectiveness of PD-1/PD-L1 inhibitors in treating refractory solid tumors. Recent data validates this synergy, showing improved survival rates in patients with recurrent head and neck squamous cell carcinoma (HNSCC) who had previously exhausted standard treatments. According to a September 2025 press release from Rakuten Medical regarding the publication of a Phase 1b/2 clinical study, the combination of ASP-1929 and pembrolizumab resulted in a median Overall Survival (OS) of 25.6 months, markedly exceeding historical benchmarks for monotherapy.

At the same time, the market is defined by the strategic global broadening of clinical development initiatives aimed at obtaining regulatory approvals in various regions outside of early adopter markets. Developers are actively expanding pivotal trials to encompass multi-regional cohorts, thereby ensuring robust data and satisfying regulatory demands in Europe and the Asia-Pacific region. This trend is illustrated by the increasing scope of late-stage studies for locoregional cancers, which are incorporating wider patient demographics to hasten commercial readiness; for example, Rakuten Medical announced in a July 2025 press release that it had expanded its global Phase 3 trial for recurrent HNSCC to enroll 412 patients, adding new clinical sites in Eastern Europe to accelerate recruitment and validation.

Key Market Players

  • Rakuten Medical, Inc.
  • Shimadzu Corporation
  • Modulight Corporation
  • Steba Biotech Ltd.
  • Luzitin SA

Report Scope

In this report, the Global Photoimmunotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Photoimmunotherapy Market, By Therapeutic Area

  • Head & Neck Cancer
  • Metastatic Melanoma
  • Others

Photoimmunotherapy Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Biotechnology & Pharmaceutical Companies
  • Others

Photoimmunotherapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Photoimmunotherapy Market.

Available Customizations:

Global Photoimmunotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Photoimmunotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Head & Neck Cancer, Metastatic Melanoma, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Biotechnology & Pharmaceutical Companies, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Photoimmunotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Photoimmunotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Photoimmunotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Photoimmunotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By End User

7. Europe Photoimmunotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Photoimmunotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By End User
    • 7.3.2. France Photoimmunotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Photoimmunotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Photoimmunotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Photoimmunotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By End User

8. Asia Pacific Photoimmunotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Photoimmunotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By End User
    • 8.3.2. India Photoimmunotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Photoimmunotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Photoimmunotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Photoimmunotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By End User

9. Middle East & Africa Photoimmunotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Photoimmunotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Photoimmunotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Photoimmunotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By End User

10. South America Photoimmunotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Photoimmunotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Photoimmunotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Photoimmunotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Photoimmunotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Rakuten Medical, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Shimadzu Corporation
  • 15.3. Modulight Corporation
  • 15.4. Steba Biotech Ltd.
  • 15.5. Luzitin SA

16. Strategic Recommendations

17. About Us & Disclaimer